Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTN NASDAQ:LFCR NASDAQ:MREO NASDAQ:NKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTNHillstream Biopharma$2.97+10.8%$3.16$1.08▼$9.08$187.43M1.411.24 million shs6.15 million shsLFCRLifecore Biomedical$5.17-4.1%$5.14$3.63▼$8.98$202.18M1.06188,541 shs874,619 shsMREOMereo BioPharma Group$0.30-1.5%$0.29$0.20▼$3.05$48.04M0.332.76 million shs2.93 million shsNKTXNkarta$2.83+1.8%$2.92$1.63▼$3.65$198.90M0.91533,639 shs1.37 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTNHillstream Biopharma+10.82%-11.34%-8.05%-6.31%+296,999,900.00%LFCRLifecore Biomedical-4.08%-6.68%+7.26%+41.26%-38.01%MREOMereo BioPharma Group-1.46%-4.14%-9.77%-9.88%-89.37%NKTXNkarta+1.80%-1.05%-11.29%+37.38%+58.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTNHillstream Biopharma$2.97+10.8%$3.16$1.08▼$9.08$187.43M1.411.24 million shs6.15 million shsLFCRLifecore Biomedical$5.17-4.1%$5.14$3.63▼$8.98$202.18M1.06188,541 shs874,619 shsMREOMereo BioPharma Group$0.30-1.5%$0.29$0.20▼$3.05$48.04M0.332.76 million shs2.93 million shsNKTXNkarta$2.83+1.8%$2.92$1.63▼$3.65$198.90M0.91533,639 shs1.37 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTNHillstream Biopharma+10.82%-11.34%-8.05%-6.31%+296,999,900.00%LFCRLifecore Biomedical-4.08%-6.68%+7.26%+41.26%-38.01%MREOMereo BioPharma Group-1.46%-4.14%-9.77%-9.88%-89.37%NKTXNkarta+1.80%-1.05%-11.29%+37.38%+58.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTNHillstream Biopharma 1.00SellN/AN/ALFCRLifecore Biomedical 2.00Hold$6.5025.73% UpsideMREOMereo BioPharma Group 2.25Hold$3.25995.75% UpsideNKTXNkarta 2.83Moderate Buy$10.75279.86% UpsideCurrent Analyst Ratings BreakdownLatest MREO, NKTX, LFCR, and CNTN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026NKTXNkarta Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026NKTXNkarta TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/17/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026LFCRLifecore Biomedical Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $6.506/10/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/3/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$9.005/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/15/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026NKTXNkarta Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.005/12/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTNHillstream BiopharmaN/AN/AN/AN/A$10.92 per shareN/ALFCRLifecore Biomedical$128.87M1.50N/AN/A$0.42 per share12.31MREOMereo BioPharma Group$500K94.69N/AN/A$0.26 per share1.14NKTXNkartaN/AN/AN/AN/A$4.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTNHillstream Biopharma-$35.92M-$1.15N/AN/AN/AN/A-31.50%-24.72%N/ALFCRLifecore BiomedicalN/A-$0.94N/AN/AN/A-25.43%-1,643.15%-14.40%8/5/2026 (Estimated)MREOMereo BioPharma Group-$41.88M-$0.05N/A14.83N/AN/A-81.28%-70.45%8/11/2026 (Estimated)NKTXNkarta-$104.08M-$1.34N/AN/AN/AN/A-30.90%-24.20%8/11/2026 (Estimated)Latest MREO, NKTX, LFCR, and CNTN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.05$11.67 millionN/A5/12/2026Q1 2026NKTXNkarta-$0.39-$0.37+$0.02-$0.37N/AN/A5/6/2026Q1 2026LFCRLifecore Biomedical-$0.29-$0.43-$0.14-$0.43$25.96 million$23.19 million3/31/2026Q4 2025CNTNHillstream BiopharmaN/A$0.54N/A$0.54N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTNHillstream BiopharmaN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTNHillstream BiopharmaN/A37.7637.76LFCRLifecore BiomedicalN/A3.792.41MREOMereo BioPharma GroupN/A6.486.48NKTXNkartaN/A12.9612.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTNHillstream Biopharma1.16%LFCRLifecore Biomedical83.36%MREOMereo BioPharma Group62.83%NKTXNkarta80.54%Insider OwnershipCompanyInsider OwnershipCNTNHillstream Biopharma6.70%LFCRLifecore Biomedical32.68%MREOMereo BioPharma Group6.50%NKTXNkarta9.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTNHillstream Biopharma269.81 million65.13 millionN/ALFCRLifecore Biomedical69037.51 million25.25 millionOptionableMREOMereo BioPharma Group40159.62 million149.24 millionOptionableNKTXNkarta14071.54 million64.53 millionOptionableMREO, NKTX, LFCR, and CNTN HeadlinesRecent News About These CompaniesNkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 26 at 8:45 AM | globenewswire.comNkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of "Moderate Buy" from AnalystsJune 20, 2026 | americanbankingnews.comNkarta Shareholders Back Directors, Auditor and Annual Say-on-PayJune 11, 2026 | tipranks.comNkarta Inc Ordinary Shares NKTXMay 16, 2026 | morningstar.comMHere's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn SituationMay 14, 2026 | finance.yahoo.comNkarta Reports First Quarter 2026 Financial Results and Corporate HighlightsMay 12, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF)April 23, 2026 | theglobeandmail.comNKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune ProgramApril 17, 2026 | zacks.comNkarta rises on FDA agreement for amended trial protocolApril 16, 2026 | msn.comNkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersApril 15, 2026 | globenewswire.comNkarta to Participate in Needham Virtual Healthcare ConferenceApril 9, 2026 | globenewswire.comNkarta Launches $100 Million At-the-Market Stock OfferingMarch 26, 2026 | tipranks.comNkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate HighlightsMarch 25, 2026 | globenewswire.comNkarta to Participate in March Investor ConferencesFebruary 27, 2026 | globenewswire.comInsider Selling: Nkarta (NASDAQ:NKTX) President Sells 5,649 Shares of StockJanuary 21, 2026 | insidertrades.comWe Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth CarefullyDecember 4, 2025 | finance.yahoo.comNkarta to Participate in Evercore Healthcare ConferenceDecember 2, 2025 | globenewswire.comNkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real ReasonNovember 22, 2025 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Rallybio (RLYB) and Nkarta (NKTX)November 11, 2025 | theglobeandmail.comNkarta price target lowered to $11 from $12 at StifelNovember 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMREO, NKTX, LFCR, and CNTN Company DescriptionsHillstream Biopharma NASDAQ:CNTN$2.97 +0.29 (+10.82%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$3.04 +0.07 (+2.32%) As of 06/26/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.Lifecore Biomedical NASDAQ:LFCR$5.17 -0.22 (-4.08%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$5.16 -0.01 (-0.19%) As of 06/26/2026 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Mereo BioPharma Group NASDAQ:MREO$0.30 0.00 (-1.46%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$0.30 +0.01 (+2.16%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Nkarta NASDAQ:NKTX$2.83 +0.05 (+1.80%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$2.80 -0.04 (-1.24%) As of 06/26/2026 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
